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Blood-derived macrophages prone 
to accumulate lysosomal lipids 
trigger oxLDL-dependent murine 
hepatic inflammation
Tom Houben  1, Yvonne Oligschlaeger1, Albert V. Bitorina1, Tim Hendrikx1, Sofie M. 
A. Walenbergh1, Marie-Hélène Lenders1, Marion J. J. Gijbels1, Fons Verheyen1, Dieter 
Lütjohann2, Marten H. Hofker3, Christoph J. Binder4,5 & Ronit Shiri-Sverdlov1
Despite the consistent rise of non-alcoholic steatohepatitis (NASH) worldwide, the mechanisms 
that govern the inflammatory aspect of this disease remain unknown. Previous research showed an 
association between hepatic inflammation and lysosomal lipid accumulation in blood-derived hepatic 
macrophages. Additionally, in vitro findings indicated that lipids, specifically derived from the oxidized 
low-density lipoprotein (oxLDL) particle, are resistant to removal from lysosomes. On this basis, we 
investigated whether lysosomal lipid accumulation in blood-derived hepatic macrophages is causally 
linked to hepatic inflammation and assessed to what extent increasing anti-oxLDL IgM autoantibodies 
can affect this mechanism. By creating a proof-of-concept mouse model, we demonstrate a causal 
role for lysosomal lipids in blood-derived hepatic macrophages in mediating hepatic inflammation and 
initiation of fibrosis. Furthermore, our findings show that increasing anti-oxLDL IgM autoantibody 
levels reduces inflammation. Hence, therapies aimed at improving lipid-induced lysosomal dysfunction 
and blocking oxLDL-formation deserve further investigation in the context of NASH.
Analogous to the steep rise of obesity and diabetes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is 
currently estimated at 25% to 45% in the general population1,2. NAFLD encompasses a spectrum of liver diseases 
that are histologically categorized in nonalcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH)3. 
Whereas hepatic steatosis without hepatic injury is referred to as NAFL, NASH is defined by a conjunction of 
steatosis and inflammation, which presents with or without fibrosis3. Though the development of inflammation 
paves the way for advanced liver diseases, the mechanisms underlying the hepatic inflammatory response are 
largely unknown. As this lack of mechanistic understanding is a key antecedent for the lack of well-defined effec-
tive therapies, it is of utmost importance to improve the knowledge regarding the mechanisms triggering hepatic 
inflammation.
Previous research from our group indicated an association between hepatic inflammation and lysosomal lipid 
accumulation inside resident Kupffer cells (KCs) as well as in blood-derived macrophages4–6. This relation was 
confirmed by the presence of cholesterol-accumulating KCs in livers of NASH patients, bolstering the notion of 
lysosomal lipid storage in hepatic macrophages as a potential mechanism for NASH7. Also, it has been shown that 
incubating macrophages with oxLDL in vitro results in the lysosomal accumulation of cholesteryl esters (CEs) 
and free cholesterol, suggesting a direct role for oxLDL in mediating lysosomal lipid-induced inflammation8,9. 
Of note, excessive accumulation of lipids in the lysosomal compartment of cells also occurs in the context of 
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Niemann-Pick type C1 (NPC1) disease. Characterized by hepatosplenomegaly, foam cell formation and hepatic 
inflammation, NPC1 patients exhibit features resembling NASH10. Therefore, it becomes evident that the pathol-
ogy of lysosomal lipid accumulation is not limited to lysosomal lipid storage diseases such as NPC1, but also plays 
a role in other lipid-associated inflammatory diseases such as NASH.
Previously, it has been demonstrated that oxLDL and the bacterium Streptococcus pneumoniae exhibit molec-
ular mimicry for the phosphorylcholine (PC) epitope, a major target for naturally occurring immunoglobulin 
M (IgM) antibodies. Immunizing mice with heat-killed Streptococcus pneumoniae has been shown to increase 
anti-oxLDL IgM autoantibodies and to reduce atherosclerotic lesion formation11 and hepatic inflammation5 in 
low-density lipoprotein receptor knockout (Ldlr−/−) mice. Unlike acetylated LDL (acLDL) and native LDL, injec-
tion of oxLDL in hyperlipidemic mice showed increased lysosomal lipid accumulation in hepatic macrophages, 
corroborating the detrimental effect of oxLDL in promoting inflammation by disturbing the physiology of the 
lysosome6. Altogether, several studies indicate that accumulation of oxLDL and associated lipids in lysosomes of 
macrophages is associated with increased inflammation. However, none of these studies provide specific evidence 
that lysosomal storage of lipids in hepatic macrophages can be a mechanistic trigger for inflammation in NASH. 
Moreover, to what extent oxLDL contributes to lysosomal lipid accumulation-induced hepatic inflammation has 
to our knowledge never been investigated.
Here, we investigated whether lysosomal lipid accumulation in blood-derived hepatic macrophages is a mech-
anistic trigger for hepatic inflammation and assessed to what extent anti-oxLDL IgM autoantibodies can affect 
this mechanism. For this purpose, lysosomal lipid accumulation in blood-derived hepatic macrophages was gen-
erated by transplanting bone marrow of Npc1-mutant (Npc1mut) or wildtype (Npc1wt) mice into Ldlr−/− mice on 
a high-fat, high-cholesterol (HFC) diet for 12 weeks. To investigate the specific contribution of oxLDL on lyso-
somal lipid-induced hepatic inflammation, mice were immunized with heat-killed Streptococcus pneumoniae5,11. 
This study describes lysosomal lipid accumulation in blood-derived hepatic macrophages as a novel mechanism 
that triggers hepatic inflammation. Moreover, our findings suggest a role for oxLDL in mediating lysosomal 
lipid-induced hepatic inflammation.
Results
Lysosomal lipid accumulation in blood-derived hepatic macrophages results in a severe 
hepatic pathological phenotype. To ensure successful bone marrow replacement, bone marrow effi-
ciency was assessed. Transplantation of both Npc1wt and Npc1mut bone marrow approximated an efficiency of 90% 
(Supplementary Table S1), proving the bone marrow transplantation successful.
Furthermore, to confirm the successful transplantation at the microscopic level, hepatic tissues were sub-
jected to electron microscopy analysis. As pointed out by the lower magnification, livers from Npc1mut-tp mice 
demonstrated dense clusters of macrophages which resembled granuloma-like structures. These structures were 
absent in Npc1wt-tp mice, indicating that these structures are related to the NPC1 mutation (Fig. 1A). Also, the 
majority of resident KCs were located adjacent to the large granulomas, containing various numbers of small 
Figure 1. Hepatic phenotype of Npc1wt-tp and Npc1mut-tp mice and IgM autoantibody titers in plasma. (A) 
Representative electron microscopy pictures of resident (Kupffer cell) and bone marrow-derived macrophages 
of Npc1wt-tp (scale bar 2 μm) and control or immunized Npc1mut-tp mice (scale bar 10 μm). Area within the 
dashed line: Npc1mut granuloma; K: Kupffer cell. (B,C) IgM EO6 antibodies (B) and IgM antibodies to copper-
oxidized (CuOx)LDL (C) were measured in plasma of mice with or without immunization at a dilution of 1:100. 
Data are expressed as relative light units (RLU)/100 ms. n = 10–11 mice/group. Asterisks indicate significant 
difference from non-immunized Npc1mut-tp mice by use of two-tailed unpaired t test. ***p < 0.001. All error 
bars are SEM.
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lipid inclusions (resembling cholesterol crystals (Supplementary Fig. S1)). No detectable differences in phenotype 
between non-immunized and immunized Npc1mut-tp mice were observed.
Relevantly, these granuloma structures were also visible at higher microscopic magnification by H&E stain-
ing (Supplementary Fig. S2). Also, relative liver and spleen weights were dramatically increased in mice trans-
planted with Npc1mut bone marrow compared to Npc1wt-tp mice, confirming the severe pathological phenotype 
(Supplementary Fig. S2). After immunization, both relative liver and spleen weight decreased in immunized 
Npc1mut-tp compared to control-treated Npc1mut-tp, suggesting that inhibition of oxLDL uptake by macrophages 
ameliorates the pathological phenotype.
Increased anti-oxLDL IgM autoantibody titers after heat-killed pneumococci immuniza-
tion. To determine whether immunization with heat-killed Streptococcus pneumoniae was performed suc-
cessfully, IgM autoantibody levels were measured in the plasma. Immunization with heat-killed pneumococci 
resulted in an increase of plasma IgM antibodies of the EO6/T15 idiotype (Fig. 1B), which bind oxLDL by spe-
cifically recognizing the phosphorylcholine epitope12. In line, increased IgM antibodies against copper-oxidized 
LDL (Cu-oxLDL) were detected in immunized mice compared to control mice (Fig. 1C). Thus, immunization 
with heat-killed pneumococci induced a modest anti-oxLDL IgM autoantibody production in Npc1mut-tp mice, 
confirming successfulness of the immunization.
Disturbances in lipid metabolism are partly restored after elevation of anti-oxLDL IgM autoan-
tibody levels. To determine the effect of lysosomal lipid accumulation in hepatic macrophages on lipid 
metabolism, we examined cholesterol and triglyceride levels in liver and plasma. Whereas hepatic cholesterol 
levels were elevated in Npc1mut-tp mice compared to Npc1wt-tp mice, immunization of Npc1mut-tp mice decreased 
hepatic cholesterol, indicating improved hepatic cholesterol metabolism upon immunization (Fig. 2A). In con-
trast, plasma cholesterol levels reduced by almost 50% in Npc1mut-tp mice compared to Npc1wt-tp mice, but did 
not differ between immunized and non-immunized Npc1mut-tp mice (Fig. 2B). Detailed investigation of the size 
of the hepatic granulomas by means of CD68 staining confirmed the presence of granulomas in Npc1mut-tp mice, 
while being absent in Npc1wt-tp mice (Fig. 2C,D). Additionally, immunizing Npc1mut-tp mice with heat-killed 
pneumococci resulted in a strong decrease of granuloma size, suggesting oxLDL as an important compound in 
disturbing cholesterol metabolism in this model (Fig. 2C,D).
Furthermore, hepatic triglyceride levels were decreased in Npc1mut-tp mice compared to Npc1wt-tp mice and 
remained similar between immunized and control-treated Npc1mut-tp mice (Fig. 2E). Analogous to hepatic tri-
glycerides, similar trends were observed in plasma triglyceride and free fatty acid levels (Fig. 2F,G).
To further define the influences on hepatic lipid metabolism, hepatic expression of genes involved in lipid 
homeostasis was examined. Compared to Npc1wt-tp mice, Npc1mut-tp mice showed increased gene expres-
sion levels of Cluster of differentiation 36 (Cd36), Scavenger receptor A (Sr-a), Niemann-Pick type C2 (Npc2) 
and ATP-binding cassette transporter G1 (Abcg1), confirming disturbance of lipid metabolism (Fig. 2H). 
Furthermore, though no differences were observed in gene expression levels of the ATP-binding cassette trans-
porter A1 (Abca1) (Fig. 2H), expression levels of all other markers were reduced upon R36A immunization of 
Npc1mut-tp mice, strengthening the importance of oxLDL to the disturbances in lipid metabolism in this model. 
Altogether, these results imply an important contribution of oxLDL to lysosomal lipid-induced disturbances in 
lipid metabolism.
OxLDL contributes to lysosomal lipid-induced hepatic inflammation. To determine whether lys-
osomal lipid accumulation in blood-derived macrophages is a trigger for hepatic inflammation, hepatic cryo-
sections were stained for the inflammatory markers Mac-1 (infiltrated macrophages and neutrophils; against 
Cd11b) and NIMP (neutrophils). Number of cells expressing both inflammatory markers was increased in 
Npc1mut-tp mice compared to Npc1wt-tp mice, supporting our hypothesis that lysosomal lipid accumulation in 
blood-derived macrophages is a direct trigger for hepatic inflammation (Fig. 3A,B). Additionally, increasing 
circulating anti-oxLDL IgM autoantibodies reduced Mac-1- and NIMP-positive cell levels (Fig. 3A–C). These 
inflammatory findings were confirmed by performing hepatic gene expression analysis of the inflammatory 
markers integrin alpha M (Itgam), tumor necrosis factor alpha (Tnfα), interleukin 12 (Il12), CXC chemokine 
receptor-4 (Cxcr4), monocyte chemoattractant protein 1 (Mcp1), Caspase-1 and CC chemokine receptor-2 (Ccr2) 
(Fig. 3D). Relevantly, while single, just infiltrated macrophages were positive for Mac-1, macrophages present 
inside the large granulomas of the Npc1mut-tp group were Mac-1-negative (Fig. 3C). This observation revealed that 
blood-derived hepatic macrophages lose the Cd11b phenotypic marker over time.
To confirm the pro-inflammatory properties of oxLDL in bone marrow-derived macrophages (BMDMs), 
wildtype BMDMs were incubated with oxLDL for 24 hours, followed by 3 hour stimulation with lipopolysac-
charide (LPS). Gene expression levels of the pro-inflammatory markers Tnfα and Mcp1 were increased upon 
oxLDL incubation, confirming the pro-inflammatory effect of oxLDL in BMDMs (Supplementary Fig. S3). Next, 
to explore the specific contribution of anti-oxLDL IgM autoantibodies to lysosomal lipid-induced inflammation 
in blood-derived macrophages, we isolated Npc1mut BMDMs and stimulated these with oxLDL, in the absence or 
presence of the anti-oxLDL antibody EO6. In the presence of EO6 antibodies, Npc1mut BMDMs stimulated with 
oxLDL demonstrated reduced inflammation, as indicated by reduced TNFα protein levels and reduced Tnfα and 
Ccr2 gene expression (Fig. 4).
Combining the in vivo and in vitro data, these results reveal for the first time that lysosomal lipid accumulation 
in blood-derived macrophages is a mechanistic trigger for lipid-induced hepatic inflammation. On top, these data 
identify an essential role for oxLDL in mediating these inflammatory effects.
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Increasing anti-oxLDL IgM autoantibodies attenuates initiation of hepatic fibrosis in mice car-
rying lysosomal-lipid storing hepatic macrophages. As hepatic fibrosis is a key symptom of active 
NASH13, we investigated whether the inflammatory trigger of lysosomal lipid accumulation in blood-derived 
hepatic macrophages can initiate hepatic fibrosis. Hepatic collagen levels, characterized by Sirius Red staining, 
were elevated in Npc1mut-tp mice compared to Npc1wt-tp mice (Fig. 5A,B), as indicated by the increased colla-
gen formation surrounding the granulomas (Fig. 5B). R36A immunization of Npc1mut-tp mice showed a trend 
towards a decrease in the level of fibrosis (Fig. 5A). Furthermore, these histological findings were confirmed by 
Figure 2. Lipid parameters. (A,B) Hepatic and plasma cholesterol levels of Npc1wt-tp and control-treated or 
immunized Npc1mut-tp mice on HFC diet. (C) Quantification of CD68 staining by measuring CD68 positive 
area. (D) Representative histological pictures of the CD68 staining (200x magnification). (E,F) Hepatic and 
plasma triglyceride levels. (G) Plasma free fatty acids. (H) Hepatic gene expression analysis of Cd36, Npc2 and 
Abcg1, Sr-a and Abca1. n = 9–11 mice/group. Gene expression data are set relative to Npc1wt-tp mice. Asterisks 
indicate significant difference from non-immunized Npc1wt-tp and Npc1mut-tp mice by use of two-tailed 
unpaired t test. *, ** and *** indicate p < 0.05, 0.01 and 0.001 resp. All error bars are SEM. TC, total cholesterol; 
TTG, total triglycerides.
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gene expression levels of the fibrotic markers, transforming growth factor beta (Tgf-β) and tissue inhibitor of 
metalloproteinase-3 (Timp3) (Fig. 5C). Altogether, these data suggest that oxLDL can initiate hepatic fibrosis by 
contributing to lysosomal lipid accumulation in blood-derived hepatic macrophages.
Discussion
Currently, the mechanisms underlying NASH are poorly understood, restricting the development of well-defined, 
effective therapies. Previously, an association was demonstrated between murine hepatic inflammation and 
lysosomal lipid accumulation in hepatic macrophages4–6. Here, we prove that lysosomal lipid accumulation in 
blood-derived hepatic macrophages is a direct trigger for hepatic inflammation and initiates fibrosis. Moreover, 
our results show that increasing anti-oxLDL IgM autoantibody levels improves inflammation and lipid metabo-
lism, suggesting that oxLDL plays a key role in mediating hepatic inflammation by promoting lipid accumulation 
in lysosomes of blood-derived hepatic macrophages. Therefore, this study provides additional insights into the 
inflammatory mechanisms driving NASH. Therapies aimed at improving lipid-induced lysosomal dysfunction 
and blocking the formation of oxLDL should therefore be investigated in the future.
Figure 3. Parameters of hepatic inflammation. (A,B) Liver sections were stained for both infiltrating 
macrophages and neutrophils (Mac-1) and neutrophils solely (NIMP) and counted. (C) Representative images 
of the Mac-1 staining (magnification × 200) after HFC feeding of Npc1wt-tp and control-treated or immunized 
Npc1mut-tp mice for 12 weeks. (D) Hepatic gene expression analysis of Itgam, Tnfα, Il12, Cxcr4, Mcp1, Caspase-1 
and Ccr2. Gene expression data were set relative to Npc1wt-tp mice. n = 9–11 mice/group. Asterisks indicate 
significant difference from non-immunized Npc1wt-tp and Npc1mut-tp mice by use of two-tailed unpaired t test. 
*p < 0.05; **p < 0.01; ***p < 0.001. All error bars are SEM.
Figure 4. EO6-treatment reduced oxLDL-induced inflammation in Npc1mut BMDMs. TNFα protein levels 
(A) and gene expression of inflammatory-related genes Tnfα and Ccr2 (B) after oxLDL loading of Npc1mut 
BMDMs in absence or presence of anti-oxLDL EO6 antibodies. All data represent n = 3 (triplicates) for each 
experimental group. Asterisks indicate significant difference from non-immunized Npc1wt-tp and Npc1mut-tp 
mice by use of two-tailed unpaired t test. *p < 0.05; ***p < 0.001. All error bars are SEM.
www.nature.com/scientificreports/
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Whereas initially viewed as the cell’s degradation center, it has become increasingly clear that the lysosome 
constitutes a central role in regulating a plethora of physiological processes14. Specifically, upon accumulation of 
macromolecules (including lipids), lysosomes gradually lose their proteolytic and regulatory function, leading to 
disturbances in processes related to apoptosis, autophagy, calcium homeostasis, protein folding and, above all, 
metabolism and inflammation15. Indeed, severely increased inflammation was observed in NPC116 and Wolman17 
disease patients, both lysosomal lipid storage disorders (LSDs), thereby linking lipid storage to inflammation. 
Likewise, previous studies by us and others have demonstrated an association between hepatic inflammation and 
lysosomal lipid accumulation5,6,18. Building on this previous knowledge, we here demonstrate for the first time 
that lysosomal lipid storage in blood-derived hepatic macrophages can be viewed as an actual trigger for hepatic 
inflammation and initiates fibrosis, two central features of NASH. Our data also imply that oxLDL contributes 
to this hepatic inflammatory mechanism. As such, we propose that lysosomal accumulation of oxLDL-derived 
lipids is a trigger for NASH.
The observation that elevations in anti-oxLDL IgM autoantibody levels could partly protect from the inflam-
matory phenotype observed in Npc1mut-tp Ldlr−/− mice suggests that an important fraction of lysosomal lipids in 
blood-derived hepatic macrophages originates from oxLDL particles. In line, while circulating levels of oxLDL 
were reported to represent 0.001% of native LDL in healthy individuals19, oxLDL levels were shown to increase up 
to 1.8% in patients with the metabolic syndrome20. Relevantly, 7β-hydroxycholesterol and 7-ketocholesterol, the 
main cholesterol oxidation products present inside oxLDL particles21,22, were previously linked to inflammatory 
processes, suggesting that cholesterol oxidation products contained in the oxLDL particle are responsible for 
eliciting inflammation23,24. Also, oxLDL-induced formation of cholesterol crystals was demonstrated to induce 
lysosomal membrane permeabilization25–27. Lysosomal membrane permeabilization and the subsequent release 
of lysosomal enzymes into the cytoplasm is a known prerequisite for activation of the inflammasome28, increased 
apoptosis29 and of necrotic cell death30, three pathways leading to increased hepatic inflammation. In line with 
these observations, blood-derived hepatic Npc1mut macrophages exhibited ruptured membrane structures, sug-
gesting that cholesterol oxidation products induced lysosomal permeabilization in these macrophages resulting 
in hepatic inflammation. However, more evidence is needed to prove the actual contribution of cholesterol oxi-
dation products to lysosomal permeabilization. Furthermore, to what extent oxLDL levels in our mouse model 
are comparable to oxLDL levels in NASH patients is not completely clear. Nevertheless, as both NASH patients31 
and Npc1−/– tp Ldlr−/− mice (described by Zhang et al.32) show increased levels of plasma oxidized lipids, our 
mouse model can be considered a proper model to investigate the contribution of oxidized lipids to the human 
NASH situation. Oxidation of lipids were also shown to occur within lysosomes33. Therefore, it is likely that the 
immunized Npc1mut-tp group still contains internally oxidized lipid products within lysosomes, which contribute 
to the hepatic inflammatory response.
Figure 5. Parameters of hepatic fibrosis. (A) Quantification of Sirius Red (collagen) staining. (B) Representative 
pictures of Sirius Red staining (original magnification, 100x) of Npc1wt-tp mice and Npc1mut-tp mice with or 
without immunization on an HFC diet for 3 months. (C) Gene expression analysis of the fibrosis markers, Tgf-β 
and Timp3. n = 9–11 mice/group. Gene expression data are shown relative to Npc1wt-tp mice by use of two-
tailed unpaired t test. *p < 0.05; **p < 0.01; ***p < 0.001. All error bars are SEM.
www.nature.com/scientificreports/
7SCIENTIfIC RepORTS | 7: 12550  | DOI:10.1038/s41598-017-13058-z
Besides cholesterol oxidation products, other components present inside or in the surface monolayer of 
oxLDL particles have also been associated with inflammatory responses. For example, oxidized phopspholipids 
and their highly reactive degradation product malondialdehyde, two lipid products identified on the surface of 
the oxLDL particle34,35, have been identified in NASH patients31,36,37. Furthermore, other lipids such as free cho-
lesterol, cholesteryl esters, proteins and their oxidized derivatives have been identified in oxLDL24. Additionally, 
while next to oxidized lipids also other non-oxidized cholesterol products contribute to the observed pathology, 
the finding that targeting specifically oxidized LDL leads to significant improvements in liver pathology provides 
evidence for an essential role for oxLDL in mediating lysosomal lipid-induced hepatic inflammation. Therefore, 
future research should aim to identify and provide detailed knowledge of the lipids specifically contained in 
oxLDL particles as this might lead to the identification of novel therapeutic targets for NASH.
Of note, besides oxLDL, also apoptotic cells expose the PC-epitope which is recognized by IgM autoanti-
bodies described in this manuscript38. As increased apoptosis has often been associated with increased levels of 
hepatic inflammation39,40, it is possible that elevations in IgM autoantibody levels reduced hepatic inflammation 
in our model via increased clearance of apoptotic cells, rather than preventing the uptake of oxLDL by hepatic 
macrophages.
The current study also describes that blood-derived hepatic macrophages, which exhibited lysosomal lipid 
accumulation due to a NPC1 mutation, lose the CD11b phenotypic marker (indicative for hematopoietic origin41) 
and gain the CD68 phenotypic marker (indicative for resident KCs41) after infiltration in the liver, suggesting that 
blood-derived macrophages have phenotypically switched into resident KCs. Additionally, embryonically-derived 
resident KCs displayed intracellular cholesterol crystal formation and engulfed the granulomas (which appeared 
to be the result of a clustering of blood-derived hepatic macrophages carrying the NPC1 mutation). Therefore, the 
inability to eliminate the inflammatory stimulus (which is derived from the granulomas created by blood-derived 
hepatic macrophages) in the liver is likely due to a combination of dysfunctional blood-derived hepatic mac-
rophages as well as the lack of a functional repertoire of resident embryonically-derived KCs to overcome this 
insult. Indeed, under inflammatory conditions, blood-derived tissue-resident macrophages were shown to 
dominate the inflammatory response in tissues42. Therefore, the findings of the current study indicate that func-
tional blood-derived hepatic macrophages are essential to overcome lipid challenges in the liver and suggest that 
improving the lysosomal function in macrophages (from hematopoietic or embryonic origin) can be beneficial 
for NASH.
Although a bone marrow-specific NPC1 mutation was used in this study, the phenomenon of lysosomal lipid 
accumulation in hepatic macrophages in NASH patients is not necessarily the result of a deficiency of the Npc1 
gene, but rather a consequence of a prolonged exposure of lipids to the liver. Furthermore, patients suffering from 
NASH traditionally show increased hepatic levels of cholesterol and triglycerides2, while our model only showed 
elevations in hepatic cholesterol levels. Therefore, the mouse model described in this study should be considered 
a proof-of-concept mouse model for the involvement of lysosomal lipid storage in blood-derived hepatic mac-
rophages to hepatic inflammation and fibrosis rather than a mouse model exactly mimicking the human situation 
of NASH.
Conclusions
In conclusion, we demonstrate here for the first time that lipid accumulation in lysosomes of blood-derived 
hepatic macrophages is a key trigger of hepatic inflammation and mediates initiation of fibrosis. Furthermore, 
increasing anti-oxLDL IgM autoantibody levels ameliorated the pathological phenotype, suggesting a key role for 
oxLDL in this process. Hence, therapies aimed at improving lipid-induced lysosomal dysfunction and blocking 
the formation of oxLDL should be further investigated in the context of NASH and might be of relevance for 
other metabolic inflammatory disorders.
Methods
Mice, bone marrow transplantation, immunization, and diet. Niemann-Pick type C1nih mutant 
(Npc1mut) mice (a kind gift from Prof. Dr. Lieberman from University of Michigan Medical School) were back-
crossed into a C57BL/6 background for more than 10 generations. Npc1mut and Ldlr−/− mice were housed under 
standard conditions and had access to food and water ad libitum. Experiments were performed according to 
Dutch regulations and approved by the Committee for Animal Welfare of Maastricht University.
To generate myeloid Npc1mut deficient Ldlr−/− mice, bone marrow transplantations were performed. 
Twenty-two week-old female Ldlr−/− mice received antibiotic water containing neomycin (100 mg/l; Gibco, 
Breda, the Netherlands) and 6*104 U/l polymycin B sulphate (Gibco, Breda, the Netherlands) one week before 
and four weeks after irradiation. One day before and on the day of the transplantation, Ldlr−/− mice were lethally 
irradiated with 6 Gray of γ-radiation, thus receiving 12 Gray in total. Lethally irradiated Ldlr−/− mice were then 
injected with 1*107 bone marrow cells donated from either Npc1mut mice or wildtype littermate controls (Npc1wt). 
In order to fully ensure bone marrow replacement, mice had a nine week recovery period. After nine weeks of 
recovery, transplanted (-tp) mice received a high-fed, high-cholesterol (HFC) diet, containing 21% butter and 
0.2% cholesterol (diet 1635; Scientific Animal Food and Engineering, Villemoissonsur-Orge, France) for 12 
weeks. Five weeks after bone marrow transplantation, mice were divided into three groups. One group received 
the equivalent of 108 colony-forming units of heat-killed R36A (unencapsulated Streptococcus pneumoniae) 
emulsified in 200 µl sterile 0.9% NaCl for the primary subcutaneous immunization. Subsequently, two intraperi-
toneal booster immunizations were administered every two weeks. The two other control groups received an 0.9% 
NaCl injection only. From the start of the diet, intraperitoneal booster immunizations were administered every 
three weeks. An overall overview of the experimental set-up is depicted in Supplementary Fig. S4.
Liver tissue was isolated and snap-frozen in liquid nitrogen and stored at −80 °C or fixed in 4% formaldehyde/
PBS. The biochemical determination of plasma cholesterol and liver triglyceride levels, electron microscopy, RNA 
www.nature.com/scientificreports/
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isolation, complementary DNA synthesis, quantitative polymerase chain reaction and auto-antibody titers against 
anti-oxLDL IgM antibodies are described extensively4,5,43–46. Liver cholesterol levels were quantified as described 
previously47.
Bone marrow-derived macrophages. Bone marrow-derived macrophages (BMDMs) were isolated from 
the tibiae and femurs of wildtype and Npc1mut mice. Cells were cultured in RPMI-1640 (GIBCO Invitrogen, Breda, 
the Netherlands) with 10% heat-inactivated fetal calf serum (Bodinco B.V. Alkmaar, the Netherlands), penicillin 
(100 U/ml), streptomycin (100 μg/ml) and L-glutamine 2 mM (all GIBCO Invitrogen, Breda, the Netherlands), 
supplemented with 20% L929-conditioned medium (LCM) for 8–9 days to generate BMDMs. After attachment, 
Npc1mut macrophages were seeded at 350,000 cells per well in 24-well plates and incubated for 24 h with oxLDL 
(25 μg/ml; Alfa Aesar: J65591, Wardhill, MA, USA), with or without anti-oxLDL EO6 antibodies (Avanti Polar 
Lipids, Alabaster, AL, USA). Wildtype macrophages underwent a similar procedure, but did not receive the EO6 
antibodies. Then cells were washed and stimulated with lipopolysaccharide (LPS; 100 ng/ml) for 3 h (wildtype 
cells) or 4 h (Npc1mut cells). Finally, supernatant was collected for protein measurements and cells were lysed for 
mRNA expression analysis.
Statistical analysis. Data were statistically analyzed by performing two-tailed non-paired t-tests using 
GraphPad Prism, version 6.0 for Windows. Data were expressed as the mean ± SEM and considered significant 
at p < 0.05. *, ** and *** indicate p < 0.05, 0.01 and 0.001 respectively. Additional explanation is provided in 
Supplementary Information.
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